04:26 PM EST, 12/11/2024 (MT Newswires) -- ACADIA Pharmaceuticals ( ACAD ) said Wednesday it closed of the sale of its rare pediatric disease priority review voucher for $150 million, before fees and expenses.

Acadia will pay Neuren Pharmaceuticals one-third of the net proceeds, under a licensing deal between the companies, the company said.

Acadia said proceeds from the sale will be used to back its commercial operations, R&D programs in central nervous system and rare diseases, as well as business development projects.